A Phase Ib/II Multicenter Open-label Modular Dose-Finding and Dose Expansion Study to Explore the Safety Tolerability and Anti-tumor Activity of Trastuzumab Deruxtecan (DS-8201a T-DXd) in Combination with other Anti-cancer Agents in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)

Brief description of study

The purpose of the study is to determine if study drug Trastuzumab Deruxtecan (T-DXd) can be given safely in combination with other cancer treatments to patients with HER2-positive metastatic breast cancer. T-DXd is a treatment for cancer that targets specific cancer cells and delivers the anti-cancer drug directly to them. The study drug T-DXd received accelerated approval by the FDA in 2019.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.